What the Psoriatic Arthritis EULAR Abstracts Tell Us
Scientific conferences like EULAR can feel overwhelming, especially when much of the research is shared through abstracts. These are short summaries of studies presented as posters or brief talks, often packed with dense data. On day one of EULAR 2025, Tiffany Westrich-Robertson, CEO of AiArthritis and a person living with non-radiographic axial spondyloarthritis, focused on abstracts related to psoriatic arthritis and what they mean for real-world patient care. To learn more, watch Tiffany’s full debrief “Psoriatic Arthritis Updates Every Patient Should Know.”
The main takeaway was that there is no one “right” treatment path, but that disease severity, symptoms, and timing matter more than ever when choosing therapy.
Join Tiffany Westrich-Robertson, CEO of AiArthritis and a patient living with axial spondyloarthritis, as she shares key research updates from EULAR 2025! In this short debrief, Tiffany breaks down the latest findings on psoriatic arthritis treatments
Early Psoriatic Arthritis and the Step-Up Question
Several abstracts revisited a long-standing question in psoriatic arthritis care: when someone is newly diagnosed, should they start with a biologic right away, or is it appropriate to begin with a conventional DMARD like methotrexate and step up if needed?
Earlier studies suggested that in early psoriatic arthritis, starting immediately with a biologic did not offer a major advantage over step-up therapy. Because of this, current recommendations often still support beginning with methotrexate or another DMARD and escalating treatment if targets are not met.
This approach fits within what is called treat-to-target care. Treat-to-target means working closely with your rheumatologist, checking in regularly, and adjusting treatment based on symptoms, exams, and lab results until you reach the best possible quality of life and disease control.
Why Disease Severity Changes the Picture
More recent data presented at EULAR added an important layer of nuance. Researchers pointed out that participants in some of the earlier studies may not have had severe psoriatic arthritis at the start.
Psoriatic arthritis is not one-size-fits-all. People can present with mild, moderate, or severe disease, and severity is not just about joint count. It can include:
- High inflammatory markers
- Swollen, hot joints
- Significant skin psoriasis
- Dactylitis, often called “sausage digits”
- Enthesitis, inflammation where tendons and ligaments attach to bone
In newer studies that included patients with more severe features early on, results looked different. After 48 weeks, patients who started biologics earlier showed significantly better outcomes compared to those who did not. This suggests that for people with aggressive or high-risk disease at onset, early biologic therapy may offer meaningful benefits.
The key message is personalization. What works well for one patient may not be the right approach for another, even if both have the same diagnosis.
Focus on Enthesitis and Dactylitis
Several abstracts specifically examined how different biologics perform for enthesitis and dactylitis, two symptoms that often drive pain and disability in psoriatic arthritis.
Enthesitis affects tendons and ligaments and can show up in many areas of the body, including the feet, hips, shoulders, and even the chest wall. Chest involvement is sometimes experienced as costochondritis (inflammation of chest cartilage), which is also common across spondyloarthritis conditions.
It was encouraging to see multiple therapies being evaluated specifically for these manifestations, rather than focusing only on joint counts. This reflects a growing recognition that patients experience disease in different ways, and treatments need to target what actually causes the most impact.
Long-Term Effectiveness Still Matters
One abstract highlighted a biologic that has now been on the market long enough to assess longer-term outcomes. In this study, people with psoriatic arthritis maintained a 50 percent improvement, measured by the ACR50 response, even three years after starting treatment.
For patients, this kind of data matters. Many people worry not just about whether a medication will work, but how long it will keep working. Seeing sustained benefit over several years provides reassurance that some therapies can remain effective over time.
What Patients Can Take From This
These abstracts reinforced several important points for people living with psoriatic arthritis:
- Early treatment decisions should consider how severe and active the disease is at diagnosis
- Step-up therapy may be appropriate for some, while others may benefit from earlier biologic use
- Treat-to-target care relies on regular communication and adjustment, not a “set it and forget it” plan
- Symptoms like enthesitis and dactylitis are increasingly being studied and taken seriously
- Long-term data on biologics is growing and shows encouraging durability for some treatments
Most importantly, these findings underline why conversations with your rheumatologist matter so much. Research is moving toward better matching the right treatment to the right patient, based not just on diagnosis, but on how the disease actually shows up in your body.
EULAR abstracts may be brief, but together they paint a clear picture: psoriatic arthritis care is becoming more individualized, more nuanced, and more responsive to what patients experience in real life.
Join the AiArthritis Go With Us Conferences Program to gain insights into the latest research and advancements in autoimmune and autoinflammatory arthritis. This unique, patient-led initiative connects individuals to cutting-edge information, empowering them to improve their healthcare journeys and advocate for change.
